|
1
|
Globocan data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
Accessed February 11, 2021.
|
|
2
|
de Groot PM, Wu CC, Carter BW and Munden
RF: The epidemiology of lung cancer. Transl Lung Cancer Res.
7:220–233. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rinaldi M, Cauchi C and Gridelli C: First
line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 17
(Suppl 5):v64–v67. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
D'Addario G and Felip E: ESMO Guidelines
Working Group. Non-small-cell lung cancer: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
19 (Suppl 2):ii39–ii40. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Zhou S, Hu X, Wang Y, Li J, Zhou L, Hao X,
Liu Y and Shi Y: Clinicopathologic characteristics and outcome of
patients with different EGFR mutations. Asia Pac J Clin Oncol.
15:166–171. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Nagahiro S, et al: Biomarker analyses and final overall
survival results from a phase III, randomized, open-label,
first-line study of gefitinib versus carboplatin/paclitaxel in
clinically selected patients with advanced non-small-cell lung
cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Douillard JY, Ostoros G, Cobo M, Ciuleanu
T, McCormack R, Webster A and Milenkova T: First-line gefitinib in
caucasian EGFR mutation-positive NSCLC patients: A phase-IV,
open-label, single-arm study. Br J Cancer. 110:55–62.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shepherd FA, Pereira J, Ciuleanu TE, Tan
EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabárbara P and
Seymour L: A randomized placebo-controlled trial of erlotinib in
patients with advanced non-small cell lung cancer (NSCLC) following
failure of 1st line or 2nd line chemotherapy. A national cancer
institute of Canada clinical trials group (NCIC CTG) trial. J Clin
Oncol. 22 (Suppl 14)(S7022)2004.
|
|
14
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (iressa survival evaluation
in lung cancer). Lancet. 366:1527–1537. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T,
Zhan P and Song Y: Treatment of uncommon EGFR mutations in
non-small cell lung cancer: New evidence and treatment. Transl Lung
Cancer Res. 8:302–316. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Miller VA, Hirsh V, Cadranel J, Chen YM,
Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al: Afatinib
versus placebo for patients with advanced, metastatic
non-small-cell lung cancer after failure of erlotinib, gefitinib,
or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase
2b/3 randomized trial. Lancet Oncol. 13:528–538. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomized phase 3 trial. Lancet
Oncol. 15:213–222. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer
M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus
gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Paz-Ares L, Tan EH, O'Byrne K, Zhang L,
Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, et al: Afatinib
versus gefitinib in patients with EGFR mutation-positive advanced
non-small-cell lung cancer: Overall survival data from the phase
IIb LUX-Lung 7 trial. Ann Oncol. 28:270–277. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schuler M, Wu YL, Hirsh V, O'Byrne K,
Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V and
Yang JC: First-line afatinib versus chemotherapy in patients with
non-small cell lung cancer and common epidermal growth factor
receptor gene mutations and brain metastases. J Thorac Oncol.
11:380–390. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Lee M, Linke R, Rosell R, Corral J, et al: Improvement
in overall survival in a randomized study that compared dacomitinib
with geftinib in patients with advanced non-small cell lung cancer
and EGFR-activating mutations. J Clin Oncol. 36:2244–2250.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ramalingam S, O'Byrne K, Boyer M, Mok T,
Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI and Paz-Ares L:
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced
nonsmall-cell lung cancer (NSCLC): Pooled subset analyses from two
randomized trials. Ann Oncol. 27:423–429. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Westover D, Zugazagoitia J, Cho BC, Lovely
CM and Paz-Ares L: Mechanisms of acquired resistance to first- and
second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29
(Suppl 1):i10–i19. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam S, Shepherd FA, He Y, Akamatsu H, Theelen W, et al:
Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Papadimitrakopoulou VA, Mok TS, Han JY,
Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J,
Hee Y, et al: Osimertinib versus platinum-pemetrexed for patients
with EGFR T790M advanced NSCLC and progression on a prior
EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Ann Oncol. 31:1536–1544. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kobayashi Y and Mitsudomi T: Not all
epidermal growth factor receptor mutations in lung cancer are
created equal: Perspectives for individualized treatment strategy.
Cancer Sci. 107:1179–1186. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang Y, Sheng J, Kang S, Fang W, Yan Y,
Hu Z, Hong S, Wu X, Qin T, Liang W and Zhang L: Patients with exon
19 deletion were associated with longer progression-free survival
compared to those with L858R mutation after first-line EGFR-TKIs
for advanced non-small cell lung cancer: A meta-analysis. PLoS One.
9(e107161)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A,
Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, et al: Impact
of specific epidermal growth factor receptor (EGFR) mutations and
clinical characteristics on outcomes after treatment with EGFR
tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung
cancer: A meta-analysis. J Clin Oncol. 33:1958–1965.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sasaki H, Endo K, Takada M, Kawahara M,
Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T,
et al: L858R EGFR mutation status correlated with
clinico-pathological features of Japanese lung cancer. Lung Cancer.
54:103–108. 2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jackman DM, Yeap BY, Sequist LV, Lindeman
N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS,
et al: Exon 19 deletion mutations of epidermal growth factor
receptor are associated with prolonged survival in non-small cell
lung cancer patients treated with gefitinib or erlotinib. Clin
Cancer Res. 12:3908–3914. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hsu WH, Yang JCH, Mok TS and Loong HH:
Overview of current systemic management of EGFR-mutant NSCLC. Ann
Oncol. 29 (Suppl 1):i3–i9. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sheng M, Wang F, Zhao Y, Li S, Wang X,
Shou T, Luo Y and Tang W: Comparison of clinical outcomes of
patients with non-small-cell lung cancer harbouring epidermal
growth factor receptor exon 19 or exon 21 mutations after tyrosine
kinase inhibitors treatment: A meta-analysis. Eur J Clin Pharmacol.
72:1–11. 2016.PubMed/NCBI View Article : Google Scholar
|
